- Home
- AKTX vs INKT Comparison
AKTX vs INKT Comparison
Compare AKTX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKTX | INKT |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 51.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AKTX | INKT |
|---|---|---|
| Price | $0.26 | $11.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.30 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.3M | 19.9K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $4.56 |
| 52 Week High | $1.73 | $76.00 |
Technical Indicators
Market Signals| Indicator | AKTX | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 47.84 |
| Support Level | $0.22 | $11.55 |
| Resistance Level | $0.47 | $12.68 |
| Average True Range (ATR) | 0.07 | 0.83 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 11.07 | 49.47 |
Price Performance
Historical ComparisonAbout AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.